<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01694004</url>
  </required_header>
  <id_info>
    <org_study_id>IRB #121111</org_study_id>
    <secondary_id>P30DK058404</secondary_id>
    <nct_id>NCT01694004</nct_id>
  </id_info>
  <brief_title>Nutrient Sensing in the Duodenum</brief_title>
  <official_title>Duodenal Lipid Sensing and Nutrient Absorption</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preliminary studies in humans suggest that the presence of lipids in the gut can modify
      glucose absorption. The overall hypothesis of this proposal is that long chain fatty acid
      sensing in the duodenum has a significant role in modifying nutrient (glucose and amino acid)
      absorption from the GI tract through a gut-brain-gut axis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigator will conduct a study in 20 lean (BMI = 19-27 kg/m2) subjects involving
      intravenous (IV) and intraduodenal (ID) infusions of glucose tracers or amino acid tracers
      and measurement of tracer rate of appearance in the plasma. An ID infusion of LCFA will allow
      the investigators to determine if LCFA can alter nutrient absorption and glucose and amino
      acid metabolism. Benzocaine will be added to the ID infusion of LCFA to inhibit nerve
      terminals in the duodenum thereby preventing gut-brain communication. Plasma levels of
      glucose and amino acid tracers, glucose oxidation (13CO2 breath test), gut hormones (CCK,
      GIP, PYY, GLP-1, ghrelin), and bioactive lipids (N-acyl phosphatidylethanolamines, NAPEs)
      will be measured during all infusion periods.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nutrient Absorption</measure>
    <time_frame>6 hours</time_frame>
    <description>Stable isotope tracers (glucose or amino acid) will be administered intravenously (IV) and intraduodenally (ID) and tracer rate of appearance in the plasma will be measured.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Substrate Oxidation</measure>
    <time_frame>6 hours</time_frame>
    <description>Oxidation of intraduodenally administered glucose or amino acid will be determined by the amount of 13C recovered from expired air.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut Hormone Levels</measure>
    <time_frame>6 hours</time_frame>
    <description>Plasma levels of gut hormones will be measured by standard RIA or ELISA assays</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Bioactive Lipids</measure>
    <time_frame>6 hours</time_frame>
    <description>Plasma levels of N-acyl phosphatidylethanolamines (NAPES)will be measured by LC-MS</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>The Effect of LCFA on Nutrient Absorption</condition>
  <arm_group>
    <arm_group_label>Benzocaine Infusion into Duodenum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The investigator will conduct a study in 20 lean (BMI = 19-27 kg/m2) subjects involving intravenous (IV) and intraduodenal (ID) infusions of glucose tracers or amino acid traces and measurement of tracer rate of appearance in the plasma. An ID infusion of LCFA will allow the investigators to determine if LCFA can alter nutrient absorption and glucose and amino acid metabolism. Benzocaine will be added to the ID infusion of LCFA to inhibit nerve terminals in the duodenum thereby preventing gut-brain communication. Plasma levels of glucose and amino acid tracers, glucose oxidation (13CO2 breath test), gut hormones (CCK, GIP, PYY, GLP-1, ghrelin), and bioactive lipids (N-acyl phosphatidylethanolamines, NAPEs) will be measured during all infusion periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benzocaine Infusion into Duodenum</intervention_name>
    <arm_group_label>Benzocaine Infusion into Duodenum</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI = 19-27 kg/m2

          -  30-55 years of age

        Exclusion Criteria:

          -  Contraindication for nasal tube placement (e.g. deviated septum, prior upper
             gastrointestinal bleed, or history of easy bleeding)

          -  Prior gastric or intestinal surgery or pancreas resection

          -  Females with a positive pregnancy test

          -  Known history of intestinal diseases including (but not limited to) inflammatory bowel
             disease (e.g. ulcerative colitis, Crohn's disease), celiac sprue, Barrett's esophagus

          -  Type 1 or type 2 diabetes

          -  Gastroenteritis (diarrhea and/or vomiting) or constipation within the past week
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robyn Tamboli, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Naji Abumrad, MD</last_name>
    <role>Study Director</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2012</study_first_submitted>
  <study_first_submitted_qc>September 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2012</study_first_posted>
  <last_update_submitted>January 23, 2018</last_update_submitted>
  <last_update_submitted_qc>January 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Robyn Tamboli</investigator_full_name>
    <investigator_title>Research Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Nutrient absorption</keyword>
  <keyword>Duodenal feeding tube</keyword>
  <keyword>Gut-brain-gut axis</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benzocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

